Perimenopause Hair Loss: Why It Starts Before Your Periods Stop

Who This Is For#

This guide is for you if:

• You still have periods, even irregular ones, and your part is widening or your ponytail feels thinner
• You are shedding more than usual and cannot tell whether it is hormonal, stress, or both
• You want to know which blood tests to ask for before spending on treatment
• You are weighing minoxidil, spironolactone or HRT and want the evidence for hair specifically

This guide is NOT for you if:

• Your periods have stopped altogether — see Menopause and Hair Loss
• Your hair loss is patchy, with smooth bare circles — see Alopecia Areata
• Your hairline is receding in a band, with eyebrow loss or scalp redness — see Frontal Fibrosing Alopecia
• Your shedding started after childbirth — see Hair Loss After Pregnancy

What Changes in Perimenopause, and Why Hair Notices First#

The estrogen-to-androgen shift#

Menopause "usually occurs between the age of 45 and 55 years, is associated with falling oestrogen levels due to ovarian follicle depletion" [2]. Perimenopause is the run-up: estrogen output becomes erratic and, on average, lower. Hair registers this: "androgens and oestrogens are involved with regulation of the hair cycle, with a reduction in anagen hairs seen in postmenopausal women" [2].

What matters is the balance, not one hormone. Androgens are falling too: a review of androgens in menopause notes that the concurrent decline in androgens contributes to menopausal symptoms, hair loss among them [4]. The ratio shifts: a review of hormonal alopecia notes that androgen excess can miniaturize scalp follicles and that hair loss can occur with the estrogen deficiency of menopause [18], so in androgen-sensitive follicles the change in balance can let miniaturization show.

Why "before your periods stop" is more than a marketing line#

Evidence for perimenopause as a distinct hair-loss phase is thin, but one review says "female pattern hair loss and frontal fibrosing alopecia have both been associated with the perimenopausal and postmenopausal states" [2]. A systematic review of 40 studies found that "alopecia—particularly frontal fibrosing and female pattern variants—demonstrated strongest postmenopausal associations" [3]. No source we found quantifies how many years before the final period hair changes begin, or how many women notice them. The mechanism makes an early start plausible: estrogen falls before periods stop, and follicles respond to the hormone, not the calendar.

The Processes That Overlap in the Same Head of Hair#

Female pattern hair loss being unmasked#

Female pattern hair loss (FPHL) is the female form of androgenetic alopecia, "the most common nonscarring alopecia," which "is characterised by distinct gradual patterned hair loss" [11]. When estrogen drops, the pattern becomes visible: a wider central part, a thinner crown, a thinner ponytail, with the frontal hairline usually kept. Under a dermatoscope the pattern is distinctive: a systematic review of 34 trichoscopy articles on androgenetic alopecia found "hair diameter variability (94.07% of patients), vellus hairs (66.45%) and the peripilar sign (43.27%)" as the commonest features [13]. Diameter variability signals miniaturization and separates FPHL from shedding. See Female Pattern Hair Loss: Treatment Options.

Telogen effluvium from hormonal flux and stress#

Telogen effluvium (TE) "is a common cause of diffuse non-scarring hair loss that is usually precipitated by physiological stress such as childbirth or sudden weight loss" [20]: many follicles enter the resting phase together, then shed months later. We found no study of TE in perimenopausal women as a defined group; the connection is inferential: hormones regulate the hair cycle [2], TE follows physiological stressors [20], and the "hypothalamic-pituitary-adrenal axis hormones" are implicated "in stress-induced alopecia" [18]. Sleep loss, mood change and heavy bleeding are plausible stressors — an inference, not a measurement. TE and FPHL often co-exist [19]; "there are no targeted treatments for the management of TE" [20], so management means identifying and removing the trigger. For sudden shedding rather than a slowly widening part, see Telogen Effluvium and the shedding check.

Frontal fibrosing alopecia — the one you must not miss#

Frontal fibrosing alopecia (FFA) is a scarring alopecia repeatedly linked to the menopausal transition [2], [3]. It destroys follicles permanently and shows as a band-like recession of the front hairline, often with eyebrow loss. It needs a dermatologist promptly; it is not something to self-treat with over-the-counter minoxidil. See Scarring Alopecia.

Thyroid and Iron: The Overlaps Worth Checking#

Thyroid#

"Strong evidence links thyroid hormones (THs) to hair loss," and "hyperthyroidism, hypothyroidism, and drug-induced hypothyroidism can induce widespread hair shedding" [17]. The same review admits "little information is available regarding the incidence and effects of thyroid dysfunction on hair problems" [17], so there is no reliable figure for how much midlife hair loss is thyroid-driven. See Thyroid Hair Loss.

Iron and ferritin#

If perimenopausal bleeding is heavy, iron matters: "in premenopausal women, the most common causes of iron deficiency anemia are menstrual blood loss and pregnancy" [14]. A meta-analysis of "thirty-six of 928 identified studies" opens by saying "there is no clear-cut evidence in the existing medical literature of an association between iron deficiency and nonscarring alopecia," then reports that "women with nonscarring alopecia had lower ferritin values at MD = -18.51 ng/dL" [15]. An older review finds "insufficient evidence to recommend giving iron supplementation therapy to patients with hair loss and iron deficiency in the absence of iron deficiency anemia" and "insufficient evidence to recommend universal screening for iron deficiency in patients with hair loss" [14]; checking ferritin in perimenopause rests on heavy bleeding as a known cause of iron deficiency, not on a hair-specific guideline.

Do not expect one agreed target: a trichology review recommends "70 micro g/L" [16], while the meta-analysis used "ferritin levels from 10 to 15 ng/dL and below" as its deficiency band [15] — different reference points, not a consensus cutoff. The nutritional review [16] also warns that "excessive intakes of nutritional supplements may actually cause hair loss and are not recommended in the absence of a proven deficiency" [16]. See Ferritin and Hair Loss and Iron Supplements.

What a Clinician Actually Does#

History, scalp examination, and a short list of blood tests#

We found no published guideline on the workup of perimenopausal hair loss specifically; what follows is assembled from the literature above and general clinic practice.

History. When the shedding began; steady thinning or sudden increase; cycle changes; any stressor, illness, surgery, crash diet or new medicine in the preceding months; heavy bleeding; family history. A TE review warns that "a common mistake of the dermatologist is to minimize the complaint" [19].

Scalp examination. A pull test for active shedding, then part width, hairline and scalp surface, with trichoscopy for the signs of FPHL [13] and the scarring changes of FFA.

Blood tests, with the caveats above:

• Full blood count and ferritin, for iron status if bleeding is heavy or diet is restricted [14]
• Thyroid function (TSH, with free thyroxine as needed) [17]
• Androgens only if there are signs of excess (acne, facial hair), which point toward PCOS rather than perimenopause
• FSH and estradiol fluctuate too much in perimenopause for a single result to settle a hair diagnosis

The full list is at Women's Hair Loss Blood Tests; the blood test tool explains each result. Take standardized part-line and crown photographs before treatment.

What the Evidence Says About Treatment#

Topical minoxidil — the only pooled randomized-trial evidence of benefit in women#

"Topical minoxidil (5% foam, 5% solution, and 2% solution) is FDA-approved for androgenetic alopecia (AGA) in men and women" [8]. The Cochrane review included "47 trials, with 5290 participants" [5]; in the pooled data from six minoxidil studies, "a greater proportion of participants (157/593) treated with minoxidil (2% and one study with 1%) reported a moderate to marked increase in their hair regrowth when compared with placebo (77/555) (risk ratio (RR) = 1.93, 95% confidence interval (CI) 1.51 to 2.47; moderate quality evidence)" [5]. More women on minoxidil than on placebo saw real regrowth, but well short of most, on "mainly moderate to low quality evidence" [5]. A common failure point is compliance with applying it "twice a day" [6]. See Minoxidil for Women, Minoxidil Shedding — an early shed is expected — and Minoxidil Side Effects. If pregnancy or breastfeeding is possible, raise it with your clinician before starting minoxidil.

Oral minoxidil — promising, off-label, and not yet trial-proven#

Low-dose oral minoxidil is off-label; there is no FDA-approved oral minoxidil product for hair loss. The only label is the antihypertensive tablet, whose warning of pericardial effusion "in about 3% of treated patients not on dialysis" [22] concerns blood-pressure doses, not hair-loss microdoses — which is why the international dosing consensus includes a baseline evaluation and monitoring before and during off-label use [7]. The same label reports that "neonatal hypertrichosis has been reported following exposure to minoxidil during pregnancy" [22]; as with every treatment in this guide, tell the prescriber if pregnancy is possible.

The hair evidence is smaller. A review of "17 studies with 634 patients" found oral minoxidil "an effective and well-tolerated treatment alternative" for those who struggle with the topical, but said "larger randomized studies" of dosing "will be needed" [6]; "low-dose 0.5-5 mg/day may also be safe and effective for female pattern hair loss and chronic telogen effluvium" [8]. In a retrospective cohort of "1404 patients" with "a mean age of 43 years," "the most frequent adverse effect was hypertrichosis (15.1%)," systemic effects included "lightheadedness (1.7%)" and "tachycardia (0.9%)," and "no life-threatening adverse effects were observed" — with the caveat of "lack of a control group" [9]. The international dosing consensus notes that "larger trials and standardized guidelines are lacking" [7]. See Oral Minoxidil.

Spironolactone — moderate benefit, heterogeneous evidence, and a pregnancy warning#

Spironolactone is a widely used antiandrogen for FPHL, usually in combination, with "clinical improvement typically requiring a minimum of 6 months" [12]. A meta-analysis pooling randomized and observational studies found "the overall rate of improved hair loss was 56.60%," higher with combined therapy "(65.80%)" than monotherapy "(43.21%)" — but "significant heterogeneity," and "hair loss did not improve or showed a modest improvement in 37.80% of all patients" [10]. Cochrane called for "further randomised controlled trials" of it [5].

Pregnancy matters more in perimenopause than people assume: irregular cycles are not infertility. The FDA label: "avoid spironolactone in pregnant women or advise a pregnant woman of the potential risk to a male fetus" [21]. If pregnancy is possible, contraception is part of the conversation. See Spironolactone for Women.

Finasteride — do not borrow the male evidence#

Finasteride is established in men, but the male evidence does not transfer: in the three Cochrane FPHL trials of finasteride 1 mg, "30/67 participants experienced improvement compared to 33/70 in the placebo group" (RR 0.95) — "finasteride was no more effective than placebo" [5]. Its FDA label states finasteride "is contraindicated in women when they are or may potentially be pregnant" [23]. See Low-Dose Finasteride and Hair Loss Medications Compared.

HRT — the honest answer is that the hair evidence is thin#

We found no randomized trial of systemic HRT with scalp hair density or regrowth as an outcome. What the reviews say:

• A Climacteric review states that HRT is not indicated for skin and hair symptoms on their own, given its risk-benefit balance, though it adds that HRT's wider potential benefits, hair included, should be discussed with women to support informed decisions [1].
• A systematic review of 40 studies found a signal in the wrong direction for one subtype: "Menopausal hormone therapy increased frontal fibrosing alopecia and rosacea risk" [3].

HRT is therefore a decision about menopausal symptoms overall, made with a clinician; no one can quote you a regrowth rate. If FFA is suspected, the association in [3] is a reason to get a dermatologist's view before starting or continuing HRT. Do not start, stop or change HRT for your hair without that conversation.

Red Flags, Timelines, and What "Working" Looks Like#

When to skip the wait and see a dermatologist#

Go directly to a dermatologist if you have any of these:

• Patchy loss with smooth bare areas
• A receding front hairline or thinning eyebrows
• Scalp pain, burning, redness, scaling or pustules
• Shiny, smooth skin where hair used to be (possible scarring)
• Hair loss alongside fever, weight change, joint pain or other systemic symptoms

Expectations#

Clinical improvement typically requires "a minimum of 6 months" [12], and for the two FDA-approved drugs, finasteride and minoxidil, "prolonged use of these drugs, is a prerequisite for enhanced treatment response" [11]. So judge any treatment on standardized photos at the 6-month mark [12], and count stabilization — the part not getting wider — as success, with regrowth a bonus. Shedding from a telogen effluvium is managed by addressing its trigger; the pattern loss underneath remains to manage. The treatment timeline tool shows month-by-month change; Emotional Impact of Hair Loss covers the rest.

Frequently Asked Questions#

Related Resources#

• Menopause and Hair Loss
• Female Pattern Hair Loss: Treatment Options
• Women's Hair Loss Blood Tests
• Minoxidil for Women
• Oral Minoxidil
• Spironolactone for Women
• Thyroid Hair Loss